Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - Xtant Medical Holdings, Inc. | v237345_8-k.htm |
EXHIBIT 99.1
|
Bacterin International Sets Third Quarter 2011 Conference Call for
|
|
Thursday, November 10, 2011 at 4:30 p.m. ET
|
BELGRADE, MT, – October 17, 2011 – Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, will hold a conference call on Thursday, November 10, 2011 at 4:30 p.m. Eastern time to discuss results for the third quarter ended September 30, 2011. Financial results will be issued in a press release after the close of the market on the same day.
Bacterin’s management will host the presentation, followed by a question and answer period.
Date: Thursday, November 10, 2011
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-In Number: 1-877-941-8416
International: 1-480-629-9808
Conference ID#:4481621
The conference call will be broadcast simultaneously and available for replay here and at the investor section of the company's Web site at www.bacterin.com.
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.
A replay of the call will be available after 7:30 p.m. Eastern time on the same day and until December 10, 2011:
Toll-free replay number:1-877-870-5176
International replay number:1-858-384-5517
Replay pin number:4481621
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE Amex: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.
Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.
Company Contact:
Guy Cook
President & CEO
Bacterin International Holdings, Inc.
Tel 406-388-0480
gcook@bacterin.com
Investor Relations:
Liolios Group, Inc.
Scott Liolios or Ron Both
Tel 949-574-3860
info@liolios.com